Intech Investment Management LLC Grows Stock Holdings in Cogent Biosciences, Inc. $COGT

by · The Markets Daily

Intech Investment Management LLC grew its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 60.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,590 shares of the technology company’s stock after acquiring an additional 23,311 shares during the period. Intech Investment Management LLC’s holdings in Cogent Biosciences were worth $2,188,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in COGT. EverSource Wealth Advisors LLC boosted its holdings in Cogent Biosciences by 1,164.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company’s stock worth $25,000 after buying an additional 652 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after buying an additional 1,333 shares in the last quarter. Strs Ohio purchased a new stake in Cogent Biosciences during the first quarter worth $36,000. Global Retirement Partners LLC purchased a new stake in Cogent Biosciences during the fourth quarter worth $37,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Cogent Biosciences by 414.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock worth $46,000 after buying an additional 1,032 shares in the last quarter.

Analyst Ratings Changes

COGT has been the topic of a number of recent analyst reports. Jefferies Financial Group initiated coverage on shares of Cogent Biosciences in a report on Monday, March 16th. They set a “buy” rating and a $55.00 price target on the stock. HC Wainwright increased their price target on shares of Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Robert W. Baird set a $35.00 price target on shares of Cogent Biosciences in a report on Thursday, February 19th. Piper Sandler increased their price target on shares of Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a report on Friday, May 29th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Cogent Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $43.73.

Check Out Our Latest Research Report on Cogent Biosciences

Cogent Biosciences Stock Performance

COGT opened at $32.26 on Thursday. The company has a quick ratio of 15.14, a current ratio of 15.14 and a debt-to-equity ratio of 0.41. The company has a market cap of $5.51 billion, a price-to-earnings ratio of -14.87 and a beta of 0.34. Cogent Biosciences, Inc. has a 52-week low of $5.49 and a 52-week high of $43.73. The firm’s fifty day simple moving average is $35.21 and its two-hundred day simple moving average is $36.72.

Cogent Biosciences (NASDAQ:COGT – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.53). Equities analysts anticipate that Cogent Biosciences, Inc. will post -2.23 earnings per share for the current fiscal year.

About Cogent Biosciences

(Free Report)

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

See Also

Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report).